Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in newly diagnosed glioblastoma
NCT04583020Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in glioblastoma (GBM), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04583020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583020.